← Back to Patent Explorer
US4357326A Expired / Lapsed US ⏱️ 0.0 years remaining

Multi-glucopyranosyl-fructofuranosyl-galactopyranosyl-glucopyranoside sulfate salts and methods of use

Assignee: Wyeth Holdings LLC
•
Filing: 1981-08-28
•
Granted: 1982-11-02
•
Expires: 2001-08-28
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract O-α-D-glucopyranosyl(1→4)-[O-α-D-glucopyranosyl-(1.fwdarw.4)] n -O-β-D-glucopyranosyl(1→6)-β-D-fructofuranosyl-O-α-D-galactopyranosyl(1→6)-α-D-glucopyranoside sulfate salts, useful as inhibitors of the complement system and the process of making such compounds.

Inventors

  • 👤 Vijay G. Nair
  • 👤 Joseph P. Joseph
  • 👤 Seymour Bernstein

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-27 06:22
CPC Classifications
C; C07; C07H; C07H3/00; C07H3/06

Claims Analysis

Total Claims: 19
Claim 1
Independent Claim 80 words
A compound selected from those of the formula: ##STR27## wherein n is an integer from zero to five, inclusive; X is --SO 3 A; and A is a pharmaceutically acceptable cation salt, wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, ammonia and substituted ammonia selected from the group consisting of trialkylamine (C 1 -C 6 ), piperidine, pyrazine, alkanolamine (C 2 -C 6 ) and cycloalkylamine (C 3 -C 6 ).
Claim 2
Dependent Claim 80 words
A compound selected from those of the formula: ##STR27## wherein n is an integer from zero to five, inclusive; X is --SO 3 A; and A is a pharmaceutically acceptable cation salt, wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, ammonia and substituted ammonia selected from the group consisting of trialkylamine (C 1 -C 6 ), piperidine, pyrazine, alkanolamine (C 2 -C 6 ) and cycloalkylamine (C 3 -C 6 ).
Claim 3
Dependent Claim 7 words
The compound according to claim 1, ##STR28##
Claim 4
Dependent Claim 7 words
The compound according to claim 1, ##STR29##
Claim 5
Dependent Claim 7 words
The compound according to claim 1, ##STR30##
Claim 6
Dependent Claim 7 words
The compound according to claim 1, ##STR31##
Claim 7
Independent Claim 109 words
A method of inhibiting the complement system in a body fluid which comprises subjecting said body fluid to the action of an effective complement inhibiting amount of a pharmaceutically acceptable compound selected from those of the formula: ##STR32## wherein n is an integer from zero to five, inclusive; X is --SO 3 A; and A is a pharmaceutically acceptable cation salt, wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, ammonia and substituted ammonia selected from the group consisting of trialkylamine (C 1 -C 6 ), piperidine, pyrazine, alkanolamine (C 2 -C 6 ) and cycloalkylamine (C 3 -C 6 ).
Claim 8
Independent Claim 109 words
A method of inhibiting the complement system in a body fluid which comprises subjecting said body fluid to the action of an effective complement inhibiting amount of a pharmaceutically acceptable compound selected from those of the formula: ##STR32## wherein n is an integer from zero to five, inclusive; X is --SO 3 A; and A is a pharmaceutically acceptable cation salt, wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, ammonia and substituted ammonia selected from the group consisting of trialkylamine (C 1 -C 6 ), piperidine, pyrazine, alkanolamine (C 2 -C 6 ) and cycloalkylamine (C 3 -C 6 ).
Claim 9
Independent Claim 105 words
A method of inhibiting the complement system in warm-blooded animal which comprises administering to said warm-blooded animal an effective complement inhibiting amount of a pharmaceutically acceptable compound selected from those of the formula: ##STR33## wherein n is an integer from zero to five, inclusive; X is --SO 3 A; and A is a pharmaceutically acceptable cation salt, wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, ammonia and substituted ammonia selected from the group consisting of trialkylamine (C 1 -C 6 ), piperidine, pyrazine, alkanolamine (C 2 -C 6 ) and cycloalkylamine (C 3 -C 6 ).
Claim 10
Independent Claim 105 words
A method of inhibiting the complement system in warm-blooded animal which comprises administering to said warm-blooded animal an effective complement inhibiting amount of a pharmaceutically acceptable compound selected from those of the formula: ##STR33## wherein n is an integer from zero to five, inclusive; X is --SO 3 A; and A is a pharmaceutically acceptable cation salt, wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, ammonia and substituted ammonia selected from the group consisting of trialkylamine (C 1 -C 6 ), piperidine, pyrazine, alkanolamine (C 2 -C 6 ) and cycloalkylamine (C 3 -C 6 ).
Claim 11
Dependent Claim 13 words
The method according to claim 6 or 7, wherein the compound is ##STR34##
Claim 12
Dependent Claim 13 words
The method according to claim 6 or 7, wherein the compound is ##STR35##
Claim 13
Dependent Claim 13 words
The method according to claim 6 or 7, wherein the compound is ##STR36##
Claim 14
Dependent Claim 13 words
The method according to claim 6 or 7, wherein the compound is ##STR37##
Claim 15
Dependent Claim 12 words
The method according to claim 7, wherein the compound is administered internally.
Claim 16
Dependent Claim 12 words
The method according to claim 7, wherein the compound is administered topically.
Claim 17
Dependent Claim 16 words
The method according to claim 7, wherein the compound is administered periodontally in the oral cavity.
Claim 18
Dependent Claim 12 words
The method according to claim 7, wherein the compound is administered intra-articularly.
Claim 19
Dependent Claim 12 words
The method according to claim 7, wherein the compound is administered parenterally.

References Cited (Backward Citations)

US4098995A Cited
US4221907A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1985-11-01 1986-05-03 1986-11-02 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1989-11-01 1990-05-03 1990-11-02 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1993-11-01 1994-05-03 1994-11-02 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag